Skip to content
StackItSmart
AHuman RCT or meta-analysis

Semaglutide

Ozempic · Wegovy · Rybelsus

Semaglutide (Ozempic, Wegovy, Rybelsus) is a long-acting GLP-1 receptor agonist peptide, given as a once-weekly subcutaneous injection or a daily oral tablet, approved for type 2 diabetes and for chronic weight management. It lowers blood glucose and produces substantial, dose-dependent weight loss (roughly 15% of body weight over ~68 weeks at the 2.4 mg weekly dose), and in people with established cardiovascular disease plus overweight/obesity it reduced major adverse cardiovascular events. The headline dangers are not from the drug being "toxic" in the steroid sense but from its potent physiological effects: very common gastrointestinal adverse effects (nausea, vomiting, diarrhea, constipation) that can cause dehydration and, rarely, kidney injury; delayed gastric emptying that leaves food in the stomach and raises the risk of pulmonary aspiration during anesthesia or endoscopy; a modestly increased risk of gallstones and gallbladder disease; and a monitored but unresolved safety signal for a rare eye condition (NAION). Weight and metabolic benefits reverse when the drug is stopped. It is not a shortcut and requires medical supervision and bloodwork. Educational information only, not medical advice; 21+.

Clinical readoutPeptide · glp1-metabolic
Hepatic strainLow
CardiovascularHigh
HPTA suppressionNone
Half-life
7 d
Route
Subcutaneous injection…
Evidence
A
Active
Once-weekly dosing for…
7 d14 d3.0 wk4.0 wk5.0 wk
Illustrative single-compartment washout · each mark = one half-life · t½ ≈ Approximately 1 week (~145-165 hours for the 2.4 mg subcutaneous formulation), a long half-life produced by albumin binding and DPP-4 resistance; this is what permits once-weekly dosing.
Pharmacology

Mechanism of action

Semaglutide is an analogue of human glucagon-like peptide-1 (GLP-1) with ~94% homology, structurally modified (an amino-acid substitution resistant to DPP-4 degradation plus a C18 fatty-diacid chain that binds albumin) to greatly prolong its action. It agonizes the GLP-1 receptor, producing: (1) glucose-dependent stimulation of insulin secretion from pancreatic beta cells; (2) suppression of inappropriately high glucagon secretion; (3) slowing of gastric emptying, which blunts post-meal glucose spikes; and (4) central action on appetite-regulating pathways that reduces hunger and caloric intake. The glucose-dependence of insulin release is why it carries low intrinsic hypoglycemia risk as monotherapy. The appetite and gastric-emptying effects drive the weight loss.
Kinetics

Pharmacokinetics

Half-life

Approximately 1 week (~145-165 hours for the 2.4 mg subcutaneous formulation), a long half-life produced by albumin binding and DPP-4 resistance; this is what permits once-weekly dosing.

Active duration

Once-weekly dosing for subcutaneous formulations; once-daily for oral. Steady state is reached after roughly 4-5 weeks of continuous dosing, and full washout after discontinuation takes approximately 5 weeks (about 5 half-lives) - relevant for peri-operative planning and pre-conception discussion with a clinician, not for evading detection.

Route

Subcutaneous injection once weekly (Ozempic/Wegovy); oral tablet once daily (Rybelsus), which has very low and variable bioavailability (~0.8%) and must be taken fasting with minimal water per its clinical pharmacology.

Metabolism & clearance

Cleared primarily by proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty-acid side chain, rather than by intact renal or hepatic excretion; consequently no dose adjustment is typically required for renal or hepatic impairment, though clinical judgment applies.

For monitoring and washout planning, not drug-test evasion.

Reported effects

Physiological & performance effects

  • Substantial dose-dependent weight loss: mean ~14.9% body-weight reduction vs ~2.4% with placebo over 68 weeks at 2.4 mg weekly, sustained to ~15.2% at 104 weeks in adults with overweight/obesity without diabetes.
  • Glycemic control in type 2 diabetes: HbA1c reductions of roughly 1.0-1.4 percentage points versus placebo with subcutaneous dosing.
  • Reduction in major adverse cardiovascular events (cardiovascular death, nonfatal MI, nonfatal stroke) in people with established cardiovascular disease and overweight/obesity but without diabetes (hazard ratio 0.80).
  • Reduction in major kidney disease progression and cardiovascular/all-cause death in type 2 diabetes with chronic kidney disease (FLOW trial).
  • Reductions in waist circumference, systolic blood pressure, and improvement in self-reported physical functioning.
  • Reduced appetite and earlier satiety via delayed gastric emptying and central appetite modulation.
  • Effects are largely reversible: about two-thirds of lost weight and most cardiometabolic improvements return within a year of stopping.
Safety

Adverse effects by system

Cardiovascular

Net cardiovascular benefit in the studied high-risk populations (reduced MACE in SELECT; reduced cardiovascular death in FLOW). A modest increase in resting heart rate (typically a few beats per minute) is an expected class pharmacodynamic effect. No signal of increased ischemic events; the drug is cardioprotective rather than cardiotoxic in trial populations.

Hepatic

No signal of drug-induced liver injury in randomized trials; not considered hepatotoxic. In a 72-week phase 2 RCT in adults with biopsy-confirmed NASH, subcutaneous semaglutide 0.4 mg produced NASH resolution with no worsening of fibrosis in 59% of patients vs 17% with placebo, though the trial did not show a significant between-group difference in fibrosis-stage improvement - suggesting a neutral-to-beneficial hepatic profile rather than toxicity.

Endocrine / HPTA

Not a sex-steroid or hormonal-axis drug; there is no evidence of direct hypothalamic-pituitary-gonadal (HPTA) suppression. Endocrine effects are metabolic: improved insulin secretion/sensitivity, low intrinsic hypoglycemia risk as monotherapy (risk rises when combined with insulin or sulfonylureas). A precautionary boxed contraindication exists for personal/family history of medullary thyroid carcinoma or MEN2, based on rodent C-cell tumors; a causal thyroid-cancer link has not been established in humans.

Reproductive

Human pregnancy safety data are inadequate; because of animal reproductive toxicity and the long half-life, use is not recommended in pregnancy. Anyone who can become pregnant should use effective contraception while on treatment, and discontinuation ahead of a planned pregnancy (allowing washout) should be discussed with a clinician. No established adverse effect on male reproductive function.

Neuropsychiatric

Depression, anxiety, and suicidal ideation have been reported in pharmacovigilance databases and prompted regulatory review; such reports were a small fraction (~1.2%) of total adverse-event reports, and controlled data have not established a causal increase in suicidality. Given rare but serious reported outcomes, mood and suicidal thoughts should be monitored and any emergence taken seriously.

Renal

No direct nephrotoxicity; large trials show renal protection in diabetic kidney disease. However, severe or prolonged gastrointestinal losses (vomiting, diarrhea) can cause volume depletion and pre-renal acute kidney injury - a dehydration-mediated, not intrinsic, renal risk.

Hematologic

No clinically significant hematologic toxicity identified; unlike anabolic-androgenic steroids it does not raise hematocrit/hemoglobin. Meta-analytic safety data show no notable hematologic signal.

Dermatologic

Injection-site reactions (subcutaneous formulations) can occur; no significant systemic dermatologic toxicity is established. Cosmetic changes attributed to rapid fat loss (facial volume loss) are a consequence of weight loss, not a direct skin toxicity.

Recovery

HPTA suppression & recovery

Suppression: None expected - semaglutide is not a hormonal/steroidal agent and does not directly suppress the hypothalamic-pituitary-gonadal axis

Because semaglutide does not suppress the HPT axis, no SERM-based recovery/PCT is indicated or applicable; single-SERM framing is not relevant to this compound. Any indirect endocrine effects of large weight changes (e.g., shifts in sex-hormone binding globulin, testosterone, or menstrual regularity) are secondary to weight loss and should be evaluated and managed by an endocrinologist rather than self-treated.

Bloodwork & vitals

Monitoring

Recommended labs & checks
Baseline and periodic HbA1c and fasting glucose (and blood glucose self-monitoring if combined with insulin or a sulfonylurea, due to hypoglycemia risk)Renal function (serum creatinine/eGFR), especially during episodes of vomiting or diarrheaLipase/amylase and clinical assessment only if pancreatitis is suspected (not routine)Weight, blood pressure, and heart rateBaseline pregnancy status/contraception counseling in people who can become pregnant

Cadence: Clinical review during the dose-escalation phase and then periodically (e.g., every 3-6 months) once stable; sooner if adverse effects emerge. All monitoring should be directed by a prescribing clinician.

Warning signs — seek care
  • Severe or persistent abdominal pain, especially radiating to the back with vomiting (possible pancreatitis) - seek urgent care
  • Right-upper-quadrant pain, fever, or jaundice (possible gallbladder disease)
  • Signs of dehydration or reduced urination after heavy vomiting/diarrhea (possible acute kidney injury)
  • Sudden painless vision loss or a new visual-field defect (possible NAION) - urgent ophthalmology assessment
  • New or worsening depression, anxiety, or any suicidal thoughts
  • Symptoms of hypoglycemia (shakiness, sweating, confusion) when used with insulin or sulfonylureas
  • Persistent vomiting or a sensation of undigested food - important to disclose before any procedure requiring sedation because of aspiration risk
Do not use if

Contraindications

  • Personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2) - precautionary boxed contraindication based on rodent C-cell tumor findings
  • Prior serious hypersensitivity reaction to semaglutide or any product component
  • History of pancreatitis - use with caution; discontinue if pancreatitis is suspected
  • Active or high-risk gallbladder/biliary disease - increased risk of gallstones and cholecystitis
  • Pregnancy and (per labeling) breastfeeding - inadequate human data plus animal reproductive toxicity; plan washout before conception with a clinician
  • Severe gastroparesis or other significant gastrointestinal motility disorder
  • Type 1 diabetes / diabetic ketoacidosis - not a substitute for insulin
  • Caution before elective surgery or endoscopy under sedation due to delayed gastric emptying and aspiration risk - inform the anesthesia/procedure team
Combinations

Interaction profile

  • ModerateWith a thermogenic stimulant: Additive cardiovascular strain
  • MajorWith insulin: Metabolic / glucose
  • ModerateWith another GLP-1 / incretin agonist: Metabolic / glucose
  • ModerateWith metformin: Metabolic / glucose
  • ModerateWith growth hormone: Metabolic / glucose
  • ContraindicatedWith DNP: Additive cardiovascular strain

Check a specific combination in the interaction checker.

Harm reduction

Reducing harm & when to stop

  • This is educational information, not medical advice, and does not create a doctor-patient relationship. Semaglutide is a prescription medication that requires clinical supervision and periodic bloodwork; 21+ only.
  • Gastrointestinal effects (nausea, vomiting, diarrhea) are very common - stay hydrated, and seek care if you cannot keep fluids down or notice reduced urination, because dehydration can injure the kidneys.
  • Because the drug delays stomach emptying, tell any anesthesiologist, surgeon, or endoscopist that you take it before any procedure requiring sedation - undigested stomach contents raise the risk of aspiration.
  • Stop and seek urgent medical care for severe abdominal pain radiating to the back (possible pancreatitis), right-upper-quadrant pain with fever/jaundice (gallbladder disease), or sudden painless vision loss (possible NAION).
  • Report any new or worsening depression, anxiety, or suicidal thoughts to a clinician immediately.
  • If you use insulin or a sulfonylurea, discuss dose adjustment with your prescriber, since combined use raises hypoglycemia risk.
  • If you can become pregnant, use effective contraception and discuss a washout period before any planned pregnancy with your clinician, given the ~5-week clearance and inadequate human pregnancy data.
  • Weight and metabolic benefits largely reverse after stopping; discontinuation decisions and long-term management should be made with a clinician, not abruptly self-directed.
  • Product identity, purity, and dosing accuracy cannot be assured outside a regulated prescription supply; this monograph does not address obtaining the compound.
Evidence

Citations (17)

Every clinical claim above is tied to a primary source. Overall evidence grade A — graded to the best available evidence for its core claims.

  1. 01

    Once-weekly subcutaneous semaglutide 2.4 mg produced mean ~14.9% body-weight loss vs ~2.4% placebo over 68 weeks; nausea and diarrhea were the most common adverse events and 4.5% discontinued for GI events.

    RCTOnce-Weekly Semaglutide in Adults with Overweight or Obesity.PMID 33567185 ↗

  2. 02

    Two-year (104-week) treatment sustained weight loss (~15.2% vs ~2.6% placebo); gastrointestinal adverse events, mostly mild-to-moderate, occurred in 82.2% vs 53.9%.

    RCTPMID 36216945 ↗

  3. 03

    Continuing vs switching to placebo after a run-in showed continued weight loss and improvements in waist circumference and systolic blood pressure; GI events occurred in 49.1% vs 26.1%.

    RCTPMID 33755728 ↗

  4. 04

    Weight and cardiometabolic benefits are largely reversible: about two-thirds of lost weight was regained within a year of stopping semaglutide.

    RCTPMID 35441470 ↗

  5. 05

    In patients with established cardiovascular disease and overweight/obesity without diabetes, semaglutide 2.4 mg reduced major adverse cardiovascular events (HR 0.80, 95% CI 0.72-0.90); adverse events led to discontinuation in 16.6% vs 8.2%.

    RCTSemaglutide and Cardiovascular Outcomes in Obesity without Diabetes.PMID 37952131 ↗

  6. 06

    In type 2 diabetes with chronic kidney disease, semaglutide 1.0 mg reduced major kidney disease events (HR 0.76), cardiovascular death (HR 0.71), and all-cause death (HR 0.80).

    RCTEffects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.PMID 38785209 ↗

  7. 07

    In type 2 diabetes, subcutaneous semaglutide reduced HbA1c by roughly 1.0-1.4 points vs placebo and increased nausea, diarrhea, and vomiting, without increasing pancreatitis or diabetic retinopathy vs placebo.

    Meta-analysisPMID 37891683 ↗

  8. 08

    Across 23 RCTs (57,911 participants) the predominant adverse events were gastrointestinal (nausea, vomiting); overall safety profile was otherwise comparable to comparators.

    Meta-analysisPMID 39046272 ↗

  9. 09

    Mechanism: GLP-1 receptor agonists augment glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and reduce caloric intake and body weight; semaglutide is long-acting via DPP-4 resistance and albumin binding.

    ReviewPMID 33068776 ↗

  10. 10

    In a 72-week, double-blind phase 2 trial in adults with biopsy-confirmed NASH and stage F1-F3 fibrosis, once-daily subcutaneous semaglutide 0.4 mg produced NASH resolution with no worsening of fibrosis in 59% of patients vs 17% with placebo, but did not show a significant between-group difference in fibrosis-stage improvement; nausea, constipation, and vomiting were more common with semaglutide.

    RCTPMID 33185364 ↗

  11. 11

    Subcutaneous semaglutide 2.4 mg has a half-life of ~145-165 hours (about one week) with median tmax 12-24 hours, supporting once-weekly dosing.

    RCTPMID 33894838 ↗

  12. 12

    Oral semaglutide has low bioavailability (~0.8%) that depends on fasting and low water volume; population PK characterized absorption, distribution, and elimination.

    CohortPMID 33969456 ↗

  13. 13

    GLP-1 receptor agonist therapy was associated with a higher incidence of residual gastric contents in fasted patients undergoing endoscopy (adjusted OR 5.8), indicating increased peri-procedural pulmonary aspiration risk.

    CohortPMID 38485835 ↗

  14. 14

    GLP-1 receptor agonist use in type 2 diabetes was associated with modestly higher rates of cholelithiasis/choledocholithiasis (aOR ~1.44), cholecystitis, and cholecystectomy; no significant difference in pancreatitis in this cohort.

    CohortPMID 42247589 ↗

  15. 15

    Semaglutide use was associated with an increased relative risk of non-arteritic anterior ischemic optic neuropathy (pooled HR 2.81) versus SGLT2 inhibitors, though absolute risk remained low.

    CohortPMID 40098249 ↗

  16. 16

    The semaglutide-NAION association is derived from retrospective epidemiological data; causality cannot be inferred, and a meta-analysis of GLP-1 RA trials found no significant NAION difference - warranting caution rather than certainty.

    ReviewPMID 40055951 ↗

  17. 17

    Psychiatric adverse-event reports (depression, anxiety, suicidal ideation) associated with GLP-1 agonists including semaglutide comprised ~1.2% of reports; severity of some cases warrants monitoring, but pharmacovigilance data do not establish causal increased suicidality.

    Case seriesPMID 38265519 ↗

Last reviewed 2026-07-06 · Verified against PubMed · Educational, not medical advice